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The Editorial on the Research Topic
New Insights into the Pathophysiology and Treatment of Neonatal Hypoxic–Ischemic 
Encephalopathy
Neonatal hypoxic–ischemic encephalopathy (HIE) is one of the leading causes of death and 
disability-adjusted life years (DALYs) in term infants (1, 2). This research topic presents a collec-
tion of one original article and four reviews covering translational research in HIE, including the 
utilization of animal models to unravel the pathophysiology of the disease, with a special focus on 
the development of novel therapies and the optimization of therapeutic hypothermia, the standard 
treatment for HIE.
In an elegant review, Davidson et al. addressed the utilization of therapeutic hypothermia for 
HIE. They discussed the evolution of hypoxic–ischemic brain damage and the optimal moment to 
start the hypothermic treatment, as well as the length and intensity of the intervention. The authors 
pointed out that, although hypothermia protocols are fairly close to optimal (starting within the first 
6 h of life and continuing for 48–72 h), they are only partly effective, since the number needed to treat 
is currently of approximately eight patients. Therefore, they argued that additional enhancements 
may come from better detection of patients who could benefit from the therapy, and by determin-
ing the optimal rate of rewarming. Moreover, the authors examined the possibility of combining 
therapeutic hypothermia with other promising experimental therapies such as erythropoietin and 
cell transplantation.
In this regard, a mini-review by Lange discussed the possibility of combining peptidylarginine 
deiminases (PADs) inhibition with therapeutic hypothermia to improve its results. PADs are 
responsible for posttranslational deimination, which impact structural and functional properties of 
proteins. Consequently, PADs have a role in different developmental processes, and their dysfunc-
tion has been linked with many degenerative and inflammatory disorders. The author discussed the 
roles of PADs after a hypoxic–ischemic insult, including aspects such as epigenetics, phagoptosis, 
and autophagy, and commented on the possible therapeutic applications of selective or non-selective 
PAD inhibition for HIE.
The review article by Rumajogee et al. summarized the etiology and pathophysiology of cerebral 
palsy, and then described the Rice-Vannucci model and 12 other rodent models of HIE, detail-
ing the characteristics, advantages, and limitations of each one of them. The authors mentioned 
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important clinical improvements for HIE that were based on 
extensive studies in preclinical models, including therapeutic 
hypothermia and the importance of maintaining cerebral 
perfusion. Moreover, they discussed sex-related distinctions 
in response to perinatal injury as well as the main limitations 
of rodent models, including differences in brain structure and 
development between rodents and humans, which may have 
important implications for the development of new therapies. 
Finally, they compared rodent versus large animal models and 
intra- versus extra-uterine models.
In their review paper, Kang and Kadam have also pointed out 
the need for establishing preclinical models to study long-term 
effects and to develop novel therapies for neonatal seizures. The 
authors described diverse etiologies of neonatal seizures, includ-
ing central nervous system infections and genetic diseases, 
while focusing on HIE. They provided a detailed discussion of 
the consequences of neonatal seizures on neurodevelopmental 
outcomes according to lesion type and severity, and called to the 
attention relevant aspects such as the evidence that prolonged 
seizures apparently lead to worsened brain injuries in HIE. 
The authors also reasoned that, because neonatal seizures are 
mostly subclinical, electroencephalographic monitoring and 
other parameters such as original lesion severity, antiepileptic 
drug efficacy, and follow-up magnetic resonance imaging are 
extremely important to estimate seizure burden and long-term 
outcomes.
This research topic also features an original article by Looney 
et al., who presented evidence that glial fibrillary acidic protein 
(GFAP) levels in umbilical cord blood serum samples do not 
differ among infants with perinatal asphyxia, infants with HIE, 
and healthy controls. Their data showed that GFAP levels were 
associated neither with the grade of HIE nor with the presence of 
developmental abnormalities at 36 months of age. Taken together 
with previous findings [Douglas-Escobar et al.; (3)], these results 
indicate that the release of the astrocytic intermediate filament 
GFAP into the blood is not an early event in HIE, although 
it has been shown that GFAP serum levels do increase at late 
time points, being associated with functional and morphologi-
cal outcomes (4, 5). Therefore, the potential role of GFAP as a 
prognostic marker deserves further investigation, as well as the 
search for early predictive biomarkers that could identify patients 
who would benefit from therapeutic hypothermia within the first 
hour after birth.
In conclusion, the articles that comprise this research topic 
provide new insights into different aspects related to HIE and may 
be useful for researchers, and health-care students and profes-
sionals who want to stay updated.
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